InMed Pharma Highlights Introduction Of IntegraSyn, Integrated CAnnabinoid Manufacturing System

Author: Benzinga Newsdesk | June 24, 2020 07:34am

InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN) (OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today introduced details of IntegraSynTM, the Company's new approach to producing pharmaceutical-grade cannabinoids. IntegraSynTM is a manufacturing system that integrates biosynthesis with other traditional drug manufacturing methods with the goal of improving production of low-cost, high quality cannabinoids.

As announced on May 5, 2020, IntegraSynTM is being developed in collaboration with contract development and manufacturing organizations in order to be able to flexibly shift from production of one cannabinoid to another. The Company recently expanded its program with one of its collaborators to include additional R&D for this manufacturing approach.

The goals of IntegraSynTM are to:

increase yields beyond traditional biosynthesis or other standard cannabinoid manufacturing methods;
reduce costs by minimizing the number of expensive manufacturing steps and use of cost-efficient starting materials;
provide manufacturing flexibility in transitioning from one cannabinoid to another;
provide access to rare cannabinoids that are otherwise impractical / expensive to extract from the plant;
be scalable to meet market demand of cannabinoids for pharmaceutical products or other purposes; and
use a sustainable approach with less environmental impact than the plant-grow-harvest-extract-purify methods.

IntegraSynTM is an integrated process that begins with a bacterial-based fermentation step generating a proprietary, high efficiency enzyme in bulk and at low cost. On an as-needed basis, this enzyme is combined with sophisticated yet cost-efficient substrates in a biotransformation vessel, leading to cannabinoid assembly. Industry standard purification processes and equipment are used to produce a high-purity cannabinoid that acts as the active pharmaceutial ingredient ("API"), which could be inventoried or used as a product for pharmaceutical R&D or for direct commercialization. In addition, the IntegraSynTM process affords the flexibility for this cannabinoid to be further processed, via either chemical synthesis or via an additional enzyme-driven biotransformation process followed by further purification, resulting in a different cannabinoid API.

Posted In: IMLFF TSX:IN